Logo image of MNPR

MONOPAR THERAPEUTICS INC (MNPR) Stock Analyst Ratings

USA - NASDAQ:MNPR - US61023L2079 - Common Stock

81.57 USD
+0.28 (+0.34%)
Last: 10/24/2025, 8:00:01 PM
81.57 USD
0 (0%)
After Hours: 10/24/2025, 8:00:01 PM
Buy % Consensus

84

ChartMill assigns a Buy % Consensus number of 84% to MNPR. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 99.28. This target is 21.71% above the current price.
MNPR was analyzed by 17 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about MNPR.
In the previous month the buy percentage consensus was at a similar level.
MNPR was analyzed by 17 analysts, which is quite many. So the average rating should be quite meaningful.
MNPR Historical Analyst RatingsMNPR Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -67 -61 -55 -49 -43 -37 -31 -25 -19 -13 -7 -1 5 10 15

Price Target & Forecast

Price Low Median Mean High 81.5760.6096.9099.28170.10 - -25.71% 18.79% 21.71% 108.53%
MNPR Current Analyst RatingMNPR Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8
Up and Down Grades
Date Firm Action Rating
2025-10-13 Barclays Initiate Overweight
2025-10-06 Raymond James Maintains Strong Buy -> Strong Buy
2025-10-02 Oppenheimer Maintains Outperform -> Outperform
2025-09-29 HC Wainwright & Co. Maintains Buy -> Buy
2025-09-25 Chardan Capital Maintains Buy -> Buy
2025-09-25 BTIG Maintains Buy -> Buy
2025-09-25 Piper Sandler Maintains Overweight -> Overweight
2025-09-23 Lake Street Initiate Buy
2025-09-16 Chardan Capital Maintains Buy -> Buy
2025-09-15 BTIG Reiterate Buy -> Buy
2025-09-09 BTIG Initiate Buy
2025-09-03 Oppenheimer Initiate Outperform
2025-09-03 Raymond James Initiate Strong Buy
2025-08-27 Cantor Fitzgerald Reiterate Overweight -> Overweight
2025-08-13 Chardan Capital Maintains Buy -> Buy
2025-07-07 Cantor Fitzgerald Initiate Overweight
2025-06-23 Chardan Capital Initiate Buy
2025-04-02 Jones Trading Downgrade Buy -> Hold
2025-04-01 HC Wainwright & Co. Reiterate Buy -> Buy
2025-01-22 HC Wainwright & Co. Maintains Buy -> Buy
2025-01-10 Piper Sandler Initiate Overweight
2024-11-11 HC Wainwright & Co. Maintains Buy -> Buy
2024-10-11 Rodman & Renshaw Initiate Buy
2024-08-14 HC Wainwright & Co. Maintains Buy -> Buy
2024-05-10 HC Wainwright & Co. Reiterate Buy -> Buy
2024-04-11 JonesTrading Upgrade Hold -> Buy
2023-06-01 HC Wainwright & Co. Reiterate Buy
2023-05-15 HC Wainwright & Co. Maintains Buy -> Buy
2023-03-29 Maxim Group Downgrade Buy -> Hold
2023-03-28 EF Hutton Maintains Buy

MONOPAR THERAPEUTICS INC / MNPR FAQ

What is the average price target for MONOPAR THERAPEUTICS INC (MNPR) stock?

17 analysts have analysed MNPR and the average price target is 99.28 USD. This implies a price increase of 21.71% is expected in the next year compared to the current price of 81.57.


Can you provide the consensus rating for MONOPAR THERAPEUTICS INC stock?

The consensus rating for MONOPAR THERAPEUTICS INC (MNPR) is 83.5294 / 100 . This indicates that analysts generally have a positive outlook on the stock.


How many analysts cover MONOPAR THERAPEUTICS INC (MNPR) stock?

The number of analysts covering MONOPAR THERAPEUTICS INC (MNPR) is 17.